Want to see AU:SPL full AI Analyst Report?
SPL Stock Chart & Stats
AU$0.38
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.38
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.77
Previous CloseN/A
Volume337.59K
Average Volume (3M)724.95K
Market Cap
AU$331.55M
Enterprise ValueAU$133.34
Total Cash (Recent Filing)AU$18.25M
Total Debt (Recent Filing)AU$790.00K
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding477,052,220
10 Day Avg. Volume366,126
30 Day Avg. Volume724,950
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)1.93
Price to Sales (P/S)7.47
P/FCF Ratio-5.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$24.00M
Bulls Say, Bears Say
Bulls Say
Proprietary Dendrimer PlatformStarpharma’s owned dendrimer platform is a durable competitive asset: it supports multiple applications (drug delivery, anti-infective, topical) and can be licensed or used for internal product development. This platform approach enables repeated partner deals and long-term IP-based upside across therapeutic and consumer markets.
Diversified Revenue ModelThe company generates revenue from licensing/collaborations (upfront, milestones, royalties), product sales and contracted R&D. That mix reduces single-product risk: licensing yields high-margin episodic upside while product sales and contract R&D provide more predictable, recurring streams to support operations over months to years.
Conservative Balance Sheet LeverageLow debt-to-equity and a healthy equity ratio provide financial flexibility for an R&D-heavy biotech. Conservative leverage lowers insolvency risk and preserves capacity to fund trials, partnerships or commercialization via non-debt options, supporting longer runway for converting R&D into commercial products.
Bears Say
Persistent UnprofitabilityThe firm remains unprofitable with negative EBIT, net margins and return on equity. Persistent losses erode equity value and mean operations are not yet self-sustaining; without durable margin improvement or commercialized high-margin products, long-term value creation depends heavily on successful R&D outcomes or partner monetization.
Weak Cash Flow ConversionNegative operating and free cash flows, plus declining FCF growth, signal limited internal cash generation to fund trials or commercialization. This creates structural reliance on external capital or milestone receipts, increasing dilution risk and constraining strategic flexibility across a 2–6 month horizon and beyond.
Revenue Lumpy From Licensing MilestonesA material portion of revenue derives from licensing and milestone payments, which are inherently lumpy and timing-dependent. That structural volatility complicates forecasting, makes operating cash unpredictable, and raises the stakes on achieving partner milestones or product approvals to sustain growth and fund ongoing R&D.
Starpharma Holdings Limited News
SPL FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest share price was AU$0.09 and its highest was AU$0.77 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is AU$331.55M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
Starpharma Holdings Limited’s upcoming earnings report date is Aug 26, 2026 which is in 32 days.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Feb 17, 2026. The company reported AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Starpharma Holdings Limited overvalued?
According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 477,052,220 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.071%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in AU:SPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Starpharma Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:SPL Sentiment 69%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
355.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.84%
Trailing 12-Months
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Technical Analysis
Immutep Ltd
―
Dimerix Limited
―
AnteoTech Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―